News Releases

Date	Title
09/06/22	Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
08/11/22	Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
08/08/22	Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
07/13/22	Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
07/08/22	Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
06/13/22	Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
06/03/22	Optinose Announces Departure of Chief Financial Officer
05/12/22	Optinose Reports First Quarter 2022 Financial Results and Operational Updates
05/05/22	Optinose Announces Reporting Date for First Quarter 2022 Financial Results
04/26/22	Optinose Announces Appointment of R. John Fletcher to the Board
04/08/22	Optinose to Present at the Needham Virtual Healthcare Conference
03/08/22	Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
03/07/22	Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
03/04/22	Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results

Keyword Search